"name","instanceType","uuid:ID","rationale","id","description","label"
"Study Design 1","StudyDesign","20738a40-1451-44cc-92c5-0d631e646774","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1","The main design for the study",""
